Baird Maintains a 'Neutral' on Onyx Pharmaceuticals (ONXX); Continue Warming Up To Kyprolis

Baird maintains a 'Neutral' on Onyx Pharmaceuticals (NASDAQ: ONXX).

Analyst, Christopher Raymond, has a positive bias toward shares of ONXX and suggests investors jump in on any meaningful pullback in the stock. He notes that anyone at the ASH/ASCO meetings the past few years took note of Kyprolis and it appears that oncologists also like this agent and have signaled a strong uptake once it's approved.

Bottom line: Interest in Kyprolis remains high and awareness continues to grow. However, SubQ Velcade remains an important competitive hurdle. Raymond said he's Staying on the sidelines for now, but increasingly like what we see. We continue to warm to this story based on this feedback.

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $46.40 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Northwest Bancshares, Inc. (NWBI) PT Lowered to $10 at Piper Sandler
• Dixon Technologies India Ltd (DIXON:IN) PT Raised to INR8,800 at HSBC
• L'Oreal SA (OR:FP) (LRLCY) PT Raised to EUR420 at HSBC